Ourself Details Performance of Serum v. Regimen in Split-Face Study

Skincare brand Ourself released results from an 8-week split-face study in which its Advanced Regenerative Serum (ARS) was evaluated against a comparator regimen of three treatment serums used in combination. Under blinded investigator grading, the single ARS-treated side showed greater efficacy than the three-product side in six of seven parameters and tied in the seventh.

Study Design

Over eight weeks, subjects applied Advanced Regenerative Serum to one side of the face and a combination of three comparator treatment serums—a vitamin C serum, a hyaluronic acid serum, and a peptide serum, to the other side. The study enrolled female subjects aged 44–71 with mild-to-moderate facial aging, evaluated using the Modified Griffiths Scale across fine lines and wrinkles, radiance and brightness, plumpness, elasticity, skin roughness, sagging and overall skin quality and appearance. A single ARS step replaced the full three-product regimen.

At week 8, the ARS-treated side showed greater improvement than the three-product regimen in six of seven parameters and tied in the seventh, according to Ourself.

According to Ourself, improvement at week 8 was graded as follows:

• Radiance/brightness: 33% improvement (vs. 23% for the three-product regimen)
• Skin roughness: 28% improvement (vs. 17% for the three-product regimen)
• Overall skin quality/appearance: 23% improvement (vs. 9% for the three-product regimen)
• Elasticity: 21% improvement (vs. 14% for the three-product regimen)
• Plumpness/loss of volume: 20% improvement (vs. 17% for the three-product regimen)
• Fine lines and wrinkles: 19% improvement (vs. 17% for the three-product regimen)
• Sagging: 13% improvement (vs. 13% for the three-product regimen) — comparable

Instrumental measurements indicated comparable hydration and barrier support between the two treatment sides at week 8, indicating that a single-formulation maintained barrier integrity as effectively as the multi-step routine, according to the company.

The study was evaluated by a blinded investigator, Dr. Carolyn Jacob, MD, FAAD, a board-certified dermatologist and founder of Chicago Cosmetic Surgery and Dermatology.